ctx131
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 13, 2023 (NCT05795595)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Mesothelioma, Malignant · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06492304 | Phase 1/Phase 2 (Phase 2) | Aug 13, 2024 | CRISPR Therapeutics |
| NCT05795595 | Phase 1/Phase 2 (Phase 2) | Mar 13, 2023 | CRISPR Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CRISPR Therapeutics | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1